logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharma raises around €1.34mln from share subscription by existing shareholder

The company said Timo Syrjälä and Acme Investments SPF Sarl, an entity wholly owned by Syrjälä has subscribed for 1,757,375 new ordinary shares at a price of €0.7598 (£0.65) each

Immunotherapy
Faron added that it will continue to explore further funding opportunities and in particular continue its discussions with potential licensing partners

Faron Pharmaceuticals Ltd (LON:FARN) has raised around €1.34mln (£1.15mln) from a share subscription by an existing shareholder to extend the company's working capital into mid-fourth quarter 2019 following on from a share placing in March.

The clinical stage biopharmaceutical company said Timo Syrjälä and Acme Investments SPF Sarl, an entity wholly owned by Syrjälä has subscribed for 1,757,375 new ordinary shares in the company at a price of €0.7598 (£0.65) each.

READ: Faron Pharma gears up for “pivotal year”; bosses convinced by Traumakine’s potential

Following the subscription, Syrjälä's total holding in the company's shares, which includes his indirect holding through Acme, is 4,519,375 shares, representing 12.14% of the enlarged issued share capital.

The group said the net proceeds of the subscription will also be applied towards advancement of the company's key products in line with the strategy set out in the recent placing on 26 March 2019 and its annual results announcement on 7 May 2019.

The company added that it will continue to explore further funding opportunities and in particular continue its discussions with potential licensing partners.

Markku Jalkanen, Faron’s CEO commented: "Following the financing raised from new and existing shareholders earlier this year, we are very pleased to receive this additional shareholder support.

“The year 2019 is significant for Faron, as we seek to advance our clinical programmes for Traumakine, and especially for Clevegen. We are highly encouraged by the confidence our shareholders continue to show in the Company."

Quick facts: Faron Pharmaceuticals Ltd

Price: 177.7 GBX

AIM:FARN
Market: AIM
Market Cap: £76.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Faron Pharma applies to list on Nasdaq First North

Headlines from the Proactive UK newsroom. Finland-based Faron Pharmaceuticals (LON:FARN) is going home and has applied to list on Nasdaq First North Growth Market, a multilateral trading facility in Helsinki. Trading is set to start on 3 December. Oriole Resources (LON:ORR) has converted...

1 day, 10 hours ago

RNS

Holdings in Company

1 day, 6 hours ago

Price Monitoring Extension

1 day, 11 hours ago

Second Price Monitoring Extn

3 days, 9 hours ago

Price Monitoring Extension

3 days, 9 hours ago

Registration of Shares

1 week, 3 days ago

2 min read